TABLE 2

Responses in auricular LNs of topical application of JAK inhibitors on TDI-induced BALB/c mice

Results are expressed as mean ± 1 S.D. (n = 6–12 per group).

Group	LN Weight	Total Cell Count	CD3⁺ T Cells	CD11c⁺CD40⁺ Cells
	mg	×10⁶	×10⁶	×10⁴
Intact	2.55 ± 0.30	2.56 ± 0.86	1.23 ± 0.42	0.61 ± 0.29
Vehicle only	6.20 ± 0.86	6.83 ± 2.35	2.99 ± 1.07	3.70 ± 1.25
Tofacitinib 0.1%	6.00 ± 0.63	6.22 ± 1.16	2.78 ± 0.53	2.96 ± 0.85
Tofacitinib 0.25%	4.79 ± 0.76**	4.37 ± 0.87^*	2.03 ± 0.45	1.42 ± 0.55**
Tofacitinib 0.5%	4.10 ± 0.75**	3.91 ± 1.03**	1.78 ± 0.46^*	0.94 ± 0.51**
Oclacitinib 0.1%	5.83 ± 1.24	6.01 ± 1.86	2.29 ± 0.59	2.25 ± 0.90^*
Oclacitinib 0.25%	2.89 ± 0.74**	2.68 ± 0.78**	1.24 ± 0.32**	0.73 ± 0.27**
Oclacitinib 0.5%	2.62 ± 0.61**	2.40 ± 0.43**	1.11 ± 0.17**	0.49 ± 0.18**

↵* P < 0.05; **P < 0.01 (Dunnett’s multiple comparisons test) versus vehicle-only control group.